Sirakoss Receives CE Mark For Osteo3 Synthetic Bone Graft Substitute
Represents New Hope for Repairing Challenging Bone Fractures Aberdeen, UK, January 31, 2019– SIRAKOSS Ltd, a developer of nanosynthetic bone graft substitutes to transform the
Represents New Hope for Repairing Challenging Bone Fractures Aberdeen, UK, January 31, 2019– SIRAKOSS Ltd, a developer of nanosynthetic bone graft substitutes to transform the
We are pleased to welcome Terri Burke to the Epidarex team. Terri joins the Epidarex transatlantic team as a Venture Partner and will focus on
The following article was published in The Times on December 26, 2018 Mention the word “charity” to most people and they’ll think of the grey-haired
New investors Alsa Holdings and UCL Technology Fund join Epidarex Capital Proceeds will allow IGEM to continue development of IgE therapeutic antibody portfolio and novel
Seasoned CEO with 30 years’ experience in the healthcare industry Edinburgh, United Kingdom, 8 November 2018 – Edinburgh Molecular Imaging (EM Imaging), the optical molecular
Roy Davis appointed as Non-Executive Chairman. Current Chair John Jeans to continue as Non-Executive Director Edinburgh Molecular Imaging Ltd (EM Imaging), the clinical phase biotechnology
Expansion in the US is consistent with NodThera’s strategy to access world class talent, foster collaborative relationships and develop deep insights into inflammasome biology to
London, 12 October 2018 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced that it has
Please see the full list of nominees and additional information regarding the awards here.
Motherwell, Scotland, 27th September 2018 – Clyde Biosciences, the leader in cardiac cell function assessment, announced today that its proprietary CellOPTIQ® High Content Assay (HCA)
© Copyright Epidarex 2022. All rights reserved.